This study evaluated the efficacy and safety of Cadonilimab (AK104), a bispecific PD-1/CTLA-4 antibody, in this population.<h4>Methods</h4>We retrospectively analyzed real-world data from driver gene-negative advanced NSCLC patients treated with AK104. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.